Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orient europharma (m) sdn bhd - clindamycin phosphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orient europharma (m) sdn bhd - beclomethasone dipropionate; formoterol fumarate dihydrate; glycopyrronium bromide -

Philippines - English - FDA (Food And Drug Administration)

n/a; distributor: am-europharma corporation - ascorbic acid ( equivalent to 568.18mg sodium ascorbate) - capsule - 500mg

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. copalia is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressants - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy.psoriatic arthritiscosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate.axial spondyloarthritis (axspa)ankylosing spondylitis (as, radiographic axial spondyloarthritis)cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids).juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - amlodipine, valsartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - heart failure - angiotensin ii antagonists, other combinations, agents acting on the renin-angiotensin system - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - enurev breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).